You searched for "disease"
What's trending Aug/Sep 2023
A round-up of the eye-related hot topics that have been trending on social media over the last few weeks. #Trufflesthekitty #Visionambassador #glassescat #ambylopiaawarness Truffles the Kitty was recently featured on Good Morning America [1]. Save the cute kitty footage for...DR-NET National DR Workshop in Tanzania: Policy, training and technology
Diabetic retinopathy (DR) is a leading cause of moderate to severe visual impairment (VI) and blindness worldwide, posing a significant public health challenge. As the prevalence of diabetes continues to rise globally, particularly in low- and middle-income countries (LMICs), the...Feb/Mar 2016 Quiz 2
History A 30-year-old male presents with a phthisical left eye and undergoes enucleation. He has some lesions in his right eye that are under ophthalmic surveillance. Figure 1 is a low power of the enucleation. Figures 2, 3 and 4...From paper to pocket: Standardising eyecare with the Malawi Eye Care App
Malawi’s population is mostly rural; the government and Christian Health Association of Malawi (CHAM) together deliver about 80% of healthcare services through local district and community health facilities [1]. However, ophthalmology specialist services are only concentrated in the central hospitals....
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema
Macular oedema (MO) is a leading cause of visual impairment in patients with diabetic retinopathy. Whilst laser photocoagulation therapy has been the proven treatment for decades, studies over the last five years have also established a role for anti-VEGF agents...
G-CSF intravitreal injections for NAION: a pilot study
In rodent models with anterior ischemic optic neuropathy (AION), granulocyte colony-stimulating factor (G-CSF) confers a neuroprotective effect on retinal ganglion cells (RGCs) via anti-apoptotic and anti-inflammatory processes. This prospective study investigated the efficacy of intravitreal injection of G-CSF for the...
Could idebenone by the solution for treating dominant optic atrophy?
Dominant optic atrophy (DOA) is a disease of the retinal ganglion cells, with no current treatment options. In most cases, DOA is caused by a mutation in the OPA1 gene. The aim of this study was to evaluate the effect...
